Zentalis Pharmaceuticals, Inc. Common Stock (ZNTL) Stock
NASDAQ · ZNTL
Key stats
- Market cap
- $185.45M
- Price / Earnings ratio
- -1.2x
- EPS (TTM)
- -$1.92
- Volume
- Loading
- 52-week high
- $6.95
- 52-week low
- $1.25
Source: third-party data provider, as of November 13, 2026
Compare with ZNTL
Recent news

Zacks Investment Research
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?
ZNTLJuly 20, 2026
Zacks Investment Research
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?
ZNTL

Stocktwits
This Small-Cap Biotech Stock Just Hit A Near 22-Month High – But This Analyst Still Expects Another 56% Rally
ZNTLApril 10, 2026
Stocktwits
This Small-Cap Biotech Stock Just Hit A Near 22-Month High – But This Analyst Still Expects Another 56% Rally
ZNTL

Zacks Investment Research
New Strong Buy Stocks for January 9th
ZNTLJanuary 9, 2025
Zacks Investment Research
New Strong Buy Stocks for January 9th
ZNTL

Benzinga
Pfizer Injects $25M Via Equity In Zentalis Pharma
ZNTLApril 27, 2022
Benzinga
Pfizer Injects $25M Via Equity In Zentalis Pharma
ZNTL
Technical indicators
- RSI 14
- 37.16
- MACD 12/26/9
- -0.25
- EMA 9 of MACD
- -0.27
- MACD histogram
- 0.02
- SMA 50
- $2.62
- Price below SMA 50
- EMA 50
- $2.55
- Price below EMA 50
- SMA 200
- $3.41
- Price below SMA 200
- EMA 200
- $2.94
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analyst ratings
Strong Sell0
Sell0
Hold0
Buy4
Strong Buy0
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
662M437M218M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-137.1M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

Zacks Investment Research
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?
ZNTLJuly 20, 2026
Zacks Investment Research
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?
ZNTL

Stocktwits
This Small-Cap Biotech Stock Just Hit A Near 22-Month High – But This Analyst Still Expects Another 56% Rally
ZNTLApril 10, 2026
Stocktwits
This Small-Cap Biotech Stock Just Hit A Near 22-Month High – But This Analyst Still Expects Another 56% Rally
ZNTL

Zacks Investment Research
New Strong Buy Stocks for January 9th
ZNTLJanuary 9, 2025
Zacks Investment Research
New Strong Buy Stocks for January 9th
ZNTL

Benzinga
Pfizer Injects $25M Via Equity In Zentalis Pharma
ZNTLApril 27, 2022
Benzinga
Pfizer Injects $25M Via Equity In Zentalis Pharma
ZNTL
About Zentalis Pharmaceuticals, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees106
CEOMs. Julie M. Eastland M.B.A.
IPO DateApr 3, 2020
HeadquartersSan Diego, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Julie M. Eastland M.B.A. | CEO, President & Director | 1964 |
| Mr. James B. Bucher J.D. | Chief Legal Officer & Corporate Secretary | 1966 |
| Dr. Ingmar Bruns M.D., Ph.D. | Chief Medical Officer | 1975 |
| Mr. Vincent A. Vultaggio | SVP of Finance & Principal Accounting Officer | 1984 |
| Mr. Robert J. DiVasto P.E. | Chief Technical Officer | 1956 |
| Ms. Wendy Chang | Chief People Officer | — |
| Mr. Haibo Wang | Chief Business Officer | — |
| Mr. Rajesh Israni | Executive VP of Regulatory Affairs & Medical Writing | — |
| Mr. Henry Gu | Senior VP & Head of Intellectual Property | — |
| Ms. Sarah Kelly | Senior Vice President of Commercial Strategy | — |
Fundamentals
Valuation
Price-to-sales ratio2.62
Price-to-book value0.86
Profitability
Return on Equity-76.00%
Return on Assets-55.00%
EBITDA$-140.24M
Trading
Average volume1,378,343
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 37.16
- MACD 12/26/9
- -0.25
- EMA 9 of MACD
- -0.27
- MACD histogram
- 0.02
- SMA 50
- $2.62
- Price below SMA 50
- EMA 50
- $2.55
- Price below EMA 50
- SMA 200
- $3.41
- Price below SMA 200
- EMA 200
- $2.94
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Analyst consensus:Buy
100% Buy
0% Hold
0% Sell
Analyst price target
- Low
- $6.00
- Average
- $8.00
- High
- $10.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +6.1 | +14.5 | ||||||||||
| 2022 | -29.4 | -13.9 | -8.5 | -43.1 | -10.9 | +18.9 | +0.6 | -7.0 | -22.3 | +13.0 | -13.6 | -4.5 |
| 2023 | +14.3 | -20.0 | -8.9 | +23.0 | +18.8 | +9.6 | -5.6 | +1.2 | -26.1 | -17.6 | -31.2 | +33.6 |
| 2024 | -25.9 | +27.5 | +3.1 | -31.4 | +5.0 | -64.1 | -7.2 | -8.7 | +13.9 | -23.5 | +8.7 | -17.2 |
| 2025 | -42.0 | +23.2 | -17.2 | +2.2 | -16.6 | -9.4 | +16.0 | +26.1 | -12.2 | -2.6 | -0.7 | -1.5 |
| 2026 | +77.4 | -4.8 | -6.4 | +56.0 | -2.2 | +21.9 | +8.7 | -19.1 | -25.3 | -24.9 | +2.2 |
Compare stocks
Market cap
$185.45M
-
-
-
Price / Earnings ratio
-1.20
-
-
-
Price / Sales ratio
2.62
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
1,378,343
-
-
-
Earnings per share
$-1.92
-
-
-



